Friday, 18 Oct 2019

You are here

IV Cyclophosphamide Equal to Mycophenolate in Lupus Nephritis

A comparison of mycophenolate mofetil (MMF) and low-dose cyclophosphamide IV (CYC) in the treatment of lupus nephritis (LN) was examined in 173 patients with class III, IV, or V LN.

In this trial, all patients received three methylprednisolone injections followed by oral corticosteroids, and then maintained on azathioprine and low-dose corticosteroid for a total of 24 weeks. The primary endpoint of treatment response at 24 weeks was assessed using the Systemic Lupus Erythematosus Disease Activity Index and adverse events.

100 patients were randomized to receive either CYC or MMF. The complete remission rate was 50% in CYC and 54% in MMF group at week 24. Gastrointestinal symptoms were significantly more frequent in patients receiving MMF (52 vs. 4%). However, other adverse events were similar.

Thus, low-dose intravenous CYC is comparable in efficacy to oral MMF in the induction treatment of less severe LN.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Protective Effects of ASA and Vasodilators in Systemic Sclerosis

A large cohort study suggests that the use of vasodilators and aspirin (ASA) in systemic sclerosis (SSc) may yield favorable  cardiovascular outcomes.

Myositis Patients at High Risk of Opportunistic Infections

Among patients with systemic rheumatic diseases, the highest incidence of opportunistic infections was seen in those with polymyositis/dermatomyositis (PM/DM), Taiwanese researchers found.

Warfarin Superior to Xarelto in Antiphospholipid Syndrome

A 3 year, multicenter, European, study shows that rivaroxaban was inferior to warfarin in preventing thrombosis in patients with antiphospholipid syndrome (APS) according to the Annals of Internal Medicine. Thus despite the inconvenience of warfarin, it remains the best option for patients with APS.

Declining Trends in Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis Mortality in the USA

Annals of Internal Medicine reports that age-adjusted mortality rates for antineutrophil cytoplasmic autoantibody–associated vasculitides (AAV) have improved over time - with a decline of nearly 2 percent per year in the United States from 1999 to 2017. Nevertheless, long-term outcomes continue to lag behind mortality rates of the general population.

Serum Interferon Predicts Lupus Flares

Elevated serum levels of interferon-α among patients whose systemic lupus erythematosus (SLE) was in remission helped predict future disease flares, European researchers found.

Among 254 SLE patients who were in remission, 26% had abnormally high serum levels of interferon-α at baseline, according to Alexis Mathian, MD, of Pitié-Salpêtrière Hospital in Paris, and colleagues.